000112747 001__ 112747
000112747 005__ 20230519145602.0
000112747 0247_ $$2doi$$a10.1002/cam4.4135
000112747 0248_ $$2sideral$$a127838
000112747 037__ $$aART-2021-127838
000112747 041__ $$aeng
000112747 100__ $$aGarrido, P.
000112747 245__ $$aLungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
000112747 260__ $$c2021
000112747 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112747 5203_ $$aObjectives: The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non-small cell lung cancer (NSCLC) patients treated with first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Another goal was to monitor the dynamics of EGFR mutations, as well as to track EGFR exon 20 p.T790M (p.T790M) resistance during treatment, as critical indicators of therapeutic efficacy and patient survival. Methods: Stage IV NSCLC patients with locally confirmed EGFR-TKI sensitizing mutations (ex19del and/or L858R) in biopsy tissue who were candidates to receive first- or second-generation EGFR-TKI as first-line therapy were included. Plasma samples were obtained at baseline and every 4 weeks during treatment until a progression-free survival (PFS) event or until study completion (72-week follow-up). The mutant allele fraction (MAF) was determined for each identified mutation using BEAMing. Results: A total of 68 of the 110 (61.8%) patients experienced a PFS event. Twenty-six patients (23.6%) presented with an emergent p.T790M mutation in plasma at some point during follow-up, preceding radiologic progression with a median of 76 (interquartile ratio: 54–111) days. Disease progression correlated with the appearance of p.T790M in plasma with a hazard ratio (HR) of 1.94 (95% confidence interval [CI], 1.48–2.54; p < 0.001). The HR for progression in patients showing increasing plasma sensitizing mutation levels (positive MAF slope) versus patients showing either decreasing or unchanged plasma mutation levels (negative or null MAF slopes) was 3.85 (95% CI, 2.01–7.36; p < 0.001). Conclusion: Detection and quantification of EGFR mutations in circulating tumor DNA using the highly sensitive BEAMing method should greatly assist in optimizing treatment decisions for advanced NSCLC patients. © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
000112747 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000112747 590__ $$a4.711$$b2021
000112747 592__ $$a1.144$$b2021
000112747 594__ $$a6.7$$b2021
000112747 591__ $$aONCOLOGY$$b106 / 245 = 0.433$$c2021$$dQ2$$eT2
000112747 593__ $$aRadiology, Nuclear Medicine and Imaging$$c2021$$dQ1
000112747 593__ $$aCancer Research$$c2021$$dQ1
000112747 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112747 700__ $$aPaz-Ares, L.
000112747 700__ $$aMajem, M.
000112747 700__ $$aMorán, T.
000112747 700__ $$aTrigo, J.M.
000112747 700__ $$aBosch-Barrera, J.
000112747 700__ $$aGarc¿a-Campelo, R.
000112747 700__ $$aGonzález-Larriba, J.L.
000112747 700__ $$aSánchez-Torres, J.M.
000112747 700__ $$aIsla, D.
000112747 700__ $$aViñolas, N.
000112747 700__ $$aCamps, C.
000112747 700__ $$aInsa, A.
000112747 700__ $$aJuan, Ó.
000112747 700__ $$aMassuti, B.
000112747 700__ $$aParedes, A.
000112747 700__ $$0(orcid)0000-0002-3662-7660$$aArtal, Á.$$uUniversidad de Zaragoza
000112747 700__ $$aLópez-Brea, M.
000112747 700__ $$aPalacios, J.
000112747 700__ $$aFelip, E.
000112747 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000112747 773__ $$g10, 17 (2021), 5878-5888$$pCancer med.$$tCancer medicine$$x2045-7634
000112747 8564_ $$s573976$$uhttps://zaguan.unizar.es/record/112747/files/texto_completo.pdf$$yVersión publicada
000112747 8564_ $$s1819529$$uhttps://zaguan.unizar.es/record/112747/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112747 909CO $$ooai:zaguan.unizar.es:112747$$particulos$$pdriver
000112747 951__ $$a2023-05-18-16:01:18
000112747 980__ $$aARTICLE